Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Completed · Phase 2

Conditions studied: Kidney Cancer

In brief

RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying the best dose of erlotinib when given together with sunitinib and to see how well they work in treating patients with unresectable or metastatic kidney cancer.

Key facts

Study ID

NCT00425386

Run by

OHSU Knight Cancer Institute

People needed

60

Starts

2006-08-01

Expected to finish

2014-03-01

Last updated by the study team

2017-05-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Southern California — Los Angeles, California, United States
• Providence Cancer Center at Providence Portland Medical Center — Portland, Oregon, United States
• OHSU Knight Cancer Institute — Portland, Oregon, United States
• Salem Hospital — Salem, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.